Drugs / BR1015-A
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07421401 | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07421388 | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07421375 | Apr → May 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BR1015-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07421375 ↗ |
| Route | Oral | “Oral Administration” NCT07421375 ↗ |